EGF / EGFR ‐ YAP 1/ TEAD 2 signaling upregulates STIM 1 in vemurafenib resistant melanoma cells

• Published in: The FEBS journal Vol. 291; no. 22; pp. 4969 - 4983
• Main Authors: Bai, Weiyu, Yan, Chenghao, Yang, Yichen, Sang, Lei, Hao, Qinggang, Yao, Xinyi, Zhang, Yingru, Yu, Jia, Wang, Yifan, Li, Xiaowen, Meng, Mingyao, Yang, Jilong, Shen, Junling, Sun, Yan, Sun, Jianwei
• Format: Journal Article
• Language: English
• Published: 01.11.2024
• ISSN: 1742-464X; 1742-4658
• DOI: 10.1111/febs.17272

Stromal interaction molecule 1 (STIM1) is the endoplasmic reticulum Ca 2+ sensor for store‐operated calcium entry and is closely associated with carcinogenesis and tumor progression. Previously, we found that STIM1 is upregulated in melanoma cells resistant to the serine/threonine‐protein kinase B‐raf inhibitor vemurafenib, although the mechanism underlying this upregulation is unknown. Here, we show that vemurafenib resistance upregulates STIM1 through an epidermal growth factor (EGF)/epidermal growth factor receptor (EGFR)‐Yes‐associated protein 1 (YAP1)/TEA domain transcription factor 2 (TEAD2) signaling axis. Vemurafenib resistance can lead to an increase in EGF and EGFR levels, causing activation of the EGFR signaling pathway, which promotes YAP1 nuclear localization to increase the expression of STIM1. Our findings not only reveal the mechanism by which vemurafenib resistance promotes STIM1 upregulation, but also provide a rationale for combined targeting of the EGF/EGFR‐YAP1/TEAD2‐STIM1 axis to improve the therapeutic efficacy of BRAF inhibitor in melanoma patients.